Department of Gastroenterology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.
Inflammatory Bowel Disease, Gastroenterology of the Rockies, Denver, CO 80218, United States.
World J Gastroenterol. 2022 Jul 7;28(25):2843-2853. doi: 10.3748/wjg.v28.i25.2843.
Patients with inflammatory bowel disease (IBD) are more likely to have concurrent immune-mediated inflammatory diseases (IMIDs) than those without IBD. IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies. Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes, and are considered to be at increased risk of requiring biologics and IBD-related surgeries, suggesting that having multiple IMIDs is a poor prognostic factor for IBD. Furthermore, IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes, suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions. In this review, we discuss the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concomitant IMIDs.
炎症性肠病(IBD)患者比无 IBD 患者更有可能同时患有免疫介导的炎症性疾病(IMIDs)。最近的研究表明,IMIDs 改变了 IBD 的表型和结果。一些研究发现,同时患有 IMIDs 的 IBD 患者可能具有更广泛或更严重的疾病表型,并且被认为更有可能需要生物制剂和与 IBD 相关的手术,这表明同时患有多种 IMIDs 是 IBD 的预后不良因素。此外,据报道,原发性硬化性胆管炎和 Takayasu 动脉炎的 IBD 患者具有独特的内镜表型,这表明同时患有 IMIDs 会影响 IBD 表型,导致特定的肠道炎症分布。在这篇综述中,我们讨论了同时患有 IMIDs 的 IBD 患者的发病机制、疾病表型和临床结局。